Form D · Pharmaceuticals

NEXTWAVE PHARMACEUTICALS Inc

Cupertino, CA · CIK 0001389718

Offering snapshot reported Jan 25, 2011 · SEC filing

Reported sold
$27.2M
Offering amount: $45.5M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 10, 2011
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 25, 2011Initial$27,229,417No comparison11SEC filing
Feb 5, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$1.7M (estimated)
Finders' fees
$0
Form D file number
021-154302

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Aquilo Partners114909

Source: Form D, filed Jan 25, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Gaurav Aggarwal Director
Linda Ara Executive
Sally Berry Executive
Michael Burdick Executive
Robert Casale Director
Craig Chambliss Executive
Steve Elms Director
Hingge Hsu Director
Frank Kung Director
Anand Mehra Director
Dayton Misfeldt Director
Jay Shepard Director, Executive
Patrick Zenner Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
20450 Stevens Creek Boulevard Suite 150
Cupertino, CA, 95014